Literature DB >> 742554

Oxatomide protects Trichinella spiralis infected mice from lethal anaphylaxis.

F De Clerck, L Van Gorp, O Vanparijs, M Borgers, F Awouters.   

Abstract

Infection with Trichinella spiralis in mice was accompanied by allergic sensitization as evidenced by anaphylactic death after intravenous injection of the antigen. Pre-treatment of the animals with oxatomide, a new orally active anti-allergic drug, resulted in significant protection of the animals; the lowest effective dose of the compound was 1.25 mg/kg orally. In contrast to cyproheptadine, oxatomide offered little protection against serotonin toxicity in mice. The present data suggest that, in this model of systemic hypersensitivity, the anti-anaphylactic effect of oxatomide can be attributed mainly to inhibition of release of allergic mediators.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 742554     DOI: 10.1007/bf01998884

Source DB:  PubMed          Journal:  Agents Actions        ISSN: 0065-4299


  12 in total

1.  5-hydroxytryptamine antagonists.

Authors:  L GYERMEK
Journal:  Pharmacol Rev       Date:  1961-09       Impact factor: 25.468

2.  Studies on the role of serotonin and mast cells in anaphylaxis of the mouse produced with soluble antigen-antibody complexes.

Authors:  S TOKUDA; R S WEISER
Journal:  J Immunol       Date:  1961-03       Impact factor: 5.422

3.  Comparative inhibition of anaphylaxis in mice by steroids, tranquilizers and other drugs.

Authors:  C L FOX; J M EINBINDER; C T NELSON
Journal:  Am J Physiol       Date:  1958-02

4.  Anaphylaxis in the mouse: possible relation of the Schultz-Dale reaction to serotonin release.

Authors:  M A FINK
Journal:  Proc Soc Exp Biol Med       Date:  1956 Aug-Sep

5.  Antihistaminic substances in histamine poisoning and anaphylaxis of mice.

Authors:  R L MAYER; D BROUSSEAU
Journal:  Proc Soc Exp Biol Med       Date:  1946-10

6.  Anaphylactic shock in the pertussis-vaccinated mouse.

Authors:  S MALKIEL; B J HARGIS
Journal:  J Allergy       Date:  1952-07

7.  Oxatomide, a new orally active drug which inhibits both the release and the effects of allergic mediators.

Authors:  F Awouters; C J Niemegeers; J Van den Berk; J M Van Neuten; F M Lenaerts; M Borgers; K H Schellekens; A Broeckaert; J De Cree; P A Janssen
Journal:  Experientia       Date:  1977-12-15

8.  Histamine sensitization of mice by Trichinella spiralis infection.

Authors:  J J Munoz; F Sogandares-Bernal; R K Bergman
Journal:  Proc Soc Exp Biol Med       Date:  1974-11

9.  Biochemical effects of mebendazole on Trichinella spiralis larvae.

Authors:  S De Nollin; H Van den Bossche
Journal:  J Parasitol       Date:  1973-12       Impact factor: 1.276

10.  The immunological response of mice infected with Trichinella spiralis. Biological and physico-chemical distinction of two homocytotropic antibodies.

Authors:  I Mota; E H Sadun; R M Bradshaw; R W Gore
Journal:  Immunology       Date:  1969-01       Impact factor: 7.397

View more
  6 in total

1.  Inhibition of histamine release from human lung in vitro by antihistamines and related drugs.

Authors:  M K Church; C F Gradidge
Journal:  Br J Pharmacol       Date:  1980-08       Impact factor: 8.739

2.  Comparative effects of oxatomide on the release of histamine from rat peritoneal mast cells.

Authors:  F De Clerck; J Van Reempts; M Borgers
Journal:  Agents Actions       Date:  1981-05

3.  Oxatomide: inhibition and stimulation of histamine release from human lung and leucocytes in vitro.

Authors:  M K Church; C F Gradidge
Journal:  Agents Actions       Date:  1980-04

4.  Pulmonary vascular actions of the antihistamine oxatomide during hypoxia.

Authors:  A Tucker
Journal:  Agents Actions       Date:  1980-06

Review 5.  Oxatomide. A review of its pharmacodynamic properties and therapeutic efficacy.

Authors:  D M Richards; R N Brogden; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1984-03       Impact factor: 9.546

6.  Lipid Cubic Systems for Sustained and Controlled Delivery of Antihistamine Drugs.

Authors:  Michele Dully; Miriama Ceresnakova; David Murray; Tewfik Soulimane; Sarah P Hudson
Journal:  Mol Pharm       Date:  2021-09-21       Impact factor: 4.939

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.